Bucher, Andreas Michael
Egger, Jan http://orcid.org/0000-0001-9194-5955
Dietz, Julia
Strecker, Ralph
Hilbert, Tom
Frodl, Eric
Wenzel, Mike
Penzkofer, Tobias
Hamm, Bernd
Chun, Felix KH
Vogl, Thomas
Kleesiek, Jens
Beeres, Martin
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (FKZ: 01KX2121, FKZ: 01KX2121, FKZ: 01KX2121, FKZ: 01KX2121, FKZ: 01KX2121, FKZ: 01KX2121, FKZ: 01KX2121)
Universitätsklinikum Essen
Article History
Received: 16 November 2023
Revised: 21 May 2024
Accepted: 23 May 2024
First Online: 26 June 2024
Declarations
:
: For this IRB approved (No. 19-299), retrospective case-control study, the hospital's PACS was searched by an independent investigator for prostate MRIs between 08/2018 and 07/2019.
: For the retrospective case-control study, no consent to participate was needed.
: For the anonymized data, no consent to publish is needed.
: R.S. and T.H. are employed by Siemens Healthineers. T.P. receives funding from Berlin Institute of Health (Advanced Clinician Scientist Grant, Platform Grant), Ministry of Education and Research (BMBF, 01KX2021 (RACOON), 01KX2121 („NUM 2.0“, RACOON), 68GX21001A, 01ZZ2315D), German Research Foundation (DFG, SFB 1340/2), European Union (H2020, CHAIMELEON: 952172, DIGITAL, EUCAIM:101100633) and reports research agreements (no personal payments, outside of submitted work) with AGO, Aprea AB, ARCAGY-GINECO, Astellas Pharma Global Inc. (APGD), Astra Zeneca, Clovis Oncology, Inc., Holaira, Incyte Corporation, Karyopharm, Lion Biotechnologies, Inc., MedImmune, Merck Sharp & Dohme Corp, Millennium Pharmaceuticals, Inc., Morphotec Inc., NovoCure Ltd., PharmaMar S.A. and PharmaMar USA, Inc., Roche, Siemens Healthineers, and TESARO Inc., and fees for a book translation (Elsevier B.V.). A.M.B.: Bayer, Guebert, Siemens Healthineers (Consulting fees and travel Support).